Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLL

Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival.

Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news